Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

Jeffrey J. Germer; Nizar N. Zein; Mohamed A. Metwally; Tanya L. Hoskin; W. Scott Harmsen; Thomas F. Smith; Robin Patel

doi:10.1016/S0732-8893(03)00149-4

Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

Jeffrey J. Germer, Nizar N. Zein, Mohamed A. Metwally, Tanya L. Hoskin, W. Scott Harmsen, Thomas F. Smith, Robin Patel

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

Original language	English (US)
Pages (from-to)	615-618
Number of pages	4
Journal	Diagnostic Microbiology and Infectious Disease
Volume	47
Issue number	4
DOIs	https://doi.org/10.1016/S0732-8893(03)00149-4
State	Published - Dec 2003

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/S0732-8893(03)00149-4

Fingerprint

Dive into the research topics of 'Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy'. Together they form a unique fingerprint.

Cite this

Germer, J. J., Zein, N. N., Metwally, M. A., Hoskin, T. L., Harmsen, W. S., Smith, T. F., & Patel, R. (2003). Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy. Diagnostic Microbiology and Infectious Disease, 47(4), 615-618. https://doi.org/10.1016/S0732-8893(03)00149-4

Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy. / Germer, Jeffrey J.; Zein, Nizar N.; Metwally, Mohamed A. et al.
In: Diagnostic Microbiology and Infectious Disease, Vol. 47, No. 4, 12.2003, p. 615-618.

Research output: Contribution to journal › Article › peer-review

Germer, JJ, Zein, NN, Metwally, MA, Hoskin, TL, Harmsen, WS, Smith, TF & Patel, R 2003, 'Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy', Diagnostic Microbiology and Infectious Disease, vol. 47, no. 4, pp. 615-618. https://doi.org/10.1016/S0732-8893(03)00149-4

Germer JJ, Zein NN, Metwally MA, Hoskin TL, Harmsen WS, Smith TF et al. Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy. Diagnostic Microbiology and Infectious Disease. 2003 Dec;47(4):615-618. doi: 10.1016/S0732-8893(03)00149-4

@article{af35325874a24f9f9c163d9d688fd87d,

title = "Comparison of the VERSANT{\texttrademark} HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR{\texttrademark} hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy",

abstract = "Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.",

author = "Germer, {Jeffrey J.} and Zein, {Nizar N.} and Metwally, {Mohamed A.} and Hoskin, {Tanya L.} and Harmsen, {W. Scott} and Smith, {Thomas F.} and Robin Patel",

year = "2003",

month = dec,

doi = "10.1016/S0732-8893(03)00149-4",

language = "English (US)",

volume = "47",

pages = "615--618",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

AU - Germer, Jeffrey J.

AU - Zein, Nizar N.

AU - Metwally, Mohamed A.

AU - Hoskin, Tanya L.

AU - Harmsen, W. Scott

AU - Smith, Thomas F.

AU - Patel, Robin

PY - 2003/12

Y1 - 2003/12

N2 - Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

AB - Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0347986543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347986543&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(03)00149-4

DO - 10.1016/S0732-8893(03)00149-4

M3 - Article

C2 - 14711484

AN - SCOPUS:0347986543

SN - 0732-8893

VL - 47

SP - 615

EP - 618

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

ER -

Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this